Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.3193730350310
   PubMed Web of Science ®Google Scholar
• Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721–1730. doi:10.1002/cncr.3049828085182
   PubMed Web of Science ®Google Scholar
• Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–2416. doi:10.1001/jama.2017.711228632866
   PubMed Web of Science ®Google Scholar
• Hisada M, Garber JE, Li FP, Fung CY, Fraumeni JF. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90(8):606–611. doi:10.1093/jnci/90.8.6069554443
   PubMedGoogle Scholar
• Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447–1453. doi:10.1053/gast.2000.2022811113065
   PubMed Web of Science ®Google Scholar
• Tan M-H, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–407. doi:10.1158/1078-0432.CCR-11-228322252256
   PubMed Web of Science ®Google Scholar
• Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 2017;3(9):1190–1196. doi:10.1001/jamaoncol.2017.042428418444
   PubMed Web of Science ®Google Scholar
• Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185–192. doi:10.1001/jama.296.2.18516835424
   PubMed Web of Science ®Google Scholar
• Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000;83(10):1301–1308. doi:10.1054/bjoc.2000.140711044354
   PubMed Web of Science ®Google Scholar
• Metcalfe KA, Poll A, Royer R, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28(3):387–391. doi:10.1200/JCO.2009.25.071220008623
   PubMed Web of Science ®Google Scholar
• Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997;60(3):505–514.9042909
   PubMed Web of Science ®Google Scholar
• Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US preventive services task force. JAMA. 2019;322(7):666–685. doi:10.1001/jama.2019.843031429902
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. doi:10.1086/37503312677558
   PubMed Web of Science ®Google Scholar
• Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–1333. doi:10.1200/JCO.2006.09.106617416853
   PubMed Web of Science ®Google Scholar
• van den Broek AJ, Van ’T Veer LJ, Hooning MJ, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. J Clin Oncol. 2016;34(5):409–418. doi:10.1200/JCO.2015.62.394226700119
   PubMed Web of Science ®Google Scholar
• Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384–1392. doi:10.1038/bjc.2011.12021487411
   PubMed Web of Science ®Google Scholar
• Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107:5. doi:10.1093/jnci/djv033
   Google Scholar
• Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–1089. doi:10.1158/1078-0432.CCR-10-256021233401
   PubMed Web of Science ®Google Scholar
• King M-C, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–646. doi:10.1126/science.108875914576434
   PubMed Web of Science ®Google Scholar
• Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282–4288. doi:10.1200/JCO.2008.16.623118779615
   PubMed Web of Science ®Google Scholar
• Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2010;119(1):13–24. doi:10.1007/s10549-009-0566-z19789974
   PubMed Web of Science ®Google Scholar
• Zhong Q, Peng H-L, Zhao X, Zhang L, Hwang W-T. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2015;21(1):211–220. doi:10.1158/1078-0432.CCR-14-181625348513
   PubMed Web of Science ®Google Scholar
• van den Broek AJ, Schmidt MK, van ’T Veer LJ, Tollenaar RAEM, van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what’s the evidence? A systematic review with meta-analysis. PLoS One. 2015;10(3):e0120189. doi:10.1371/journal.pone.012018925816289
   PubMed Web of Science ®Google Scholar
• Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine. 2016;95(40):e4975. doi:10.1097/MD.000000000000497527749552
   PubMed Web of Science ®Google Scholar
• Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;11:CD002748. doi:10.1002/14651858.CD002748.pub3
   Web of Science ®Google Scholar
• Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723–733. doi:10.1007/s10549-019-05345-231302855
   PubMed Web of Science ®Google Scholar
• Bedrosian I, Hu C-Y, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401–409. doi:10.1093/jnci/djq01820185801
   PubMedGoogle Scholar
• Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226. doi:10.1136/bmj.g22624519767
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23(19):4275–4286. doi:10.1200/JCO.2005.10.08015795415
   PubMed Web of Science ®Google Scholar
• Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22(15):3971–3981. doi:10.1158/1078-0432.CCR-15-146526979395
   PubMed Web of Science ®Google Scholar
• King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158–2164. doi:10.1200/JCO.2010.29.404121464413
   PubMed Web of Science ®Google Scholar
• Zeichner SB, Zeichner SB, Ruiz AL, Markward NJ, Rodriguez E. Improved long-term survival with contralateral prophylactic mastectomy among young women. Asian Pac J Cancer Prev. 2014;15(3):1155–1162. doi:10.7314/apjcp.2014.15.3.115524606434
   PubMedGoogle Scholar
• Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–87. doi:10.1093/jnci/djn44219141781
   PubMedGoogle Scholar
• Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24(16):2437–2443. doi:10.1200/JCO.2005.02.788816636335
   PubMed Web of Science ®Google Scholar
• Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328–2335. doi:10.1200/JCO.2004.04.03315197194
   PubMed Web of Science ®Google Scholar
• Evron E, Ben-David AM, Goldberg H, et al. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer. Ann Oncol. 2019;30(3):412–417. doi:10.1093/annonc/mdy51530475942
   PubMed Web of Science ®Google Scholar
• Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13–21. doi:10.1200/JCO.2014.57.057225092775
   PubMed Web of Science ®Google Scholar
• Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378–1385. doi:10.1001/jamaoncol.2017.100728715532
   PubMed Web of Science ®Google Scholar
• Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, Phase 3 trial. Lancet Oncol. 2018;19(4):497–509. doi:10.1016/S1470-2045(18)30111-629501363
   PubMed Web of Science ®Google Scholar
• Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29(12):2341–2347. doi:10.1093/annonc/mdy46030335131
   PubMed Web of Science ®Google Scholar
• Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497–1508. doi:10.1093/annonc/mdy12729873695
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158. doi:10.1126/science.aam734428302823
   PubMed Web of Science ®Google Scholar
• Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38(5):388–394. doi:10.1200/JCO.19.0130431461380
   PubMed Web of Science ®Google Scholar
• Sonnenblick A, de Azambuja E, Azim HA, Piccart M. An update on PARP inhibitors–moving to the adjuvant setting. Nat Rev Clin Oncol. 2015;12(1):27–41. doi:10.1038/nrclinonc.2014.16325286972
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi:10.1056/NEJMoa170645028578601
   PubMed Web of Science ®Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566. doi:10.1093/annonc/mdz01230689707
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763. doi:10.1056/NEJMoa180290530110579
   PubMed Web of Science ®Google Scholar
• A phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer - full text view - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02163694. Accessed 47, 2020.
   Google Scholar
• Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–637. doi:10.1038/s41591-018-0009-729713086
   PubMed Web of Science ®Google Scholar
• Damineni S, Rao VR, Kumar S, et al. Germline mutations of TP53 gene in breast cancer. Tumour Biol. 2014;35(9):9219–9227. doi:10.1007/s13277-014-2176-624929325
   PubMedGoogle Scholar
• Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52(10):2984–2986.1581912
   PubMed Web of Science ®Google Scholar
• Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2(4):475–484. doi:10.1177/194760191141346621779515
   PubMedGoogle Scholar
• Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673–3681. doi:10.1002/cncr.3024827496084
   PubMed Web of Science ®Google Scholar
• McBride KA, Ballinger ML, Killick E, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11(5):260–271. doi:10.1038/nrclinonc.2014.4124642672
   PubMed Web of Science ®Google Scholar
• Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001;96(4):238–242. doi:10.1002/ijc.102111474498
   PubMed Web of Science ®Google Scholar
• Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104. doi:10.1186/1748-717X-5-10421059199
   PubMed Web of Science ®Google Scholar
• Rath MG, Masciari S, Gelman R, et al. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat. 2013;139(1):193–198. doi:10.1007/s10549-012-2375-z23580068
   PubMed Web of Science ®Google Scholar
• Kappel S, Janschek E, Wolf B, et al. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family. Breast Cancer Res Treat. 2015;151(3):671–678. doi:10.1007/s10549-015-3424-125981898
   PubMed Web of Science ®Google Scholar
• Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74(6):957–967. doi:10.1016/0092-8674(93)90719-78402885
   PubMed Web of Science ®Google Scholar
• Yehia L, Ngeow J, Eng C. PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Invest. 2019;129(2):452–464. doi:10.1172/JCI12127730614812
   PubMed Web of Science ®Google Scholar
• Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95(1):29–39. doi:10.1016/s0092-8674(00)81780-89778245
   PubMed Web of Science ®Google Scholar
• Luen SJ, Asher R, Lee CK, et al. Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast cancer: a secondary analysis of the BIG 1-98 randomized clinical trial. JAMA Oncol. 2018;4(10):1335–1343. doi:10.1001/jamaoncol.2018.177829902286
   PubMed Web of Science ®Google Scholar
• Stern HM, Gardner H, Burzykowski T, et al. PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance. Clin Cancer Res. 2015;21(9):2065–2074. doi:10.1158/1078-0432.CCR-14-299325649019
   PubMed Web of Science ®Google Scholar
• André F, Hurvitz S, Fasolo A, et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol. 2016;34(18):2115–2124. doi:10.1200/JCO.2015.63.916127091708
   PubMed Web of Science ®Google Scholar
• Kim S-B, Dent R, Im S-A, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Oncol. 2017;18(10):1360–1372. doi:10.1016/S1470-2045(17)30450-328800861
   PubMed Web of Science ®Google Scholar
• Oliveira M, Saura C, Nuciforo P, et al. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019;30(8):1289–1297. doi:10.1093/annonc/mdz17731147675
   PubMed Web of Science ®Google Scholar
• Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157–170. doi:10.1016/j.cell.2006.11.04217218262
   PubMed Web of Science ®Google Scholar
• Bassi C, Ho J, Srikumar T, et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science. 2013;341(6144):395–399. doi:10.1126/science.123618823888040
   PubMed Web of Science ®Google Scholar
• Minami D, Takigawa N, Takeda H, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2013;11(2):140–148. doi:10.1158/1541-7786.MCR-12-040123239809
   PubMed Web of Science ®Google Scholar
• Lin F, de Gooijer MC, Roig EM, et al. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res. 2014;20(10):2703–2713. doi:10.1158/1078-0432.CCR-14-008424647572
   PubMed Web of Science ®Google Scholar
• Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6–7):315–322. doi:10.1002/emmm.20090004120049735
   PubMed Web of Science ®Google Scholar
• Gruber JJ, Afghahi A, Hatton A, Scott D, McMillan A, Ford JM, Telli ML. Talazoparib beyond BRCA: a phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes. J Clin Oncol. 2019 Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3006. Accessed April 7, 2020.
   Web of Science ®Google Scholar
• Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436–444. doi:10.1136/jmg.2009.07423720591882
   PubMed Web of Science ®Google Scholar
• Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer. 2010;13(1):1–10. doi:10.1007/s10120-009-0531-x20373070
   PubMed Web of Science ®Google Scholar
• van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–374. doi:10.1136/jmedgenet-2015-10309425979631
   PubMed Web of Science ®Google Scholar
• Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32. doi:10.1001/jamaoncol.2014.16826182300
   PubMed Web of Science ®Google Scholar
• Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297(21):2360–2372. doi:10.1001/jama.297.21.236017545690
   PubMed Web of Science ®Google Scholar
• Ping Z, Siegal GP, Harada S, et al. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast. Oncotarget. 2016;7(49):80655–80663. doi:10.18632/oncotarget.1301927811364
   PubMedGoogle Scholar
• Colleoni M, Russo L, Dellapasqua S. Adjuvant therapies for special types of breast cancer. Breast. 2011;20(Suppl 3):S153–S157. doi:10.1016/S0960-9776(11)70315-022015285
   PubMed Web of Science ®Google Scholar
• Teo K, Gómez-Cuadrado L, Tenhagen M, et al. E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Sci Rep. 2018;8(1):15454. doi:10.1038/s41598-018-33525-530337563
   PubMed Web of Science ®Google Scholar
• Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39(2):165–167. doi:10.1038/ng195917200668
   PubMed Web of Science ®Google Scholar
• Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39(2):162–164. doi:10.1038/ng194717200671
   PubMed Web of Science ®Google Scholar
• Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71(6):2222–2229. doi:10.1158/0008-5472.CAN-10-395821285249
   PubMed Web of Science ®Google Scholar
• Yang X, Leslie G, Doroszuk A, et al. Cancer Risks associated with germline PALB2 pathogenic variants: an International Study of 524 families. J Clin Oncol. 2020;38(7):674–685. doi:10.1200/JCO.19.0190731841383
   PubMed Web of Science ®Google Scholar
• Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016;13(9):581–588. doi:10.1038/nrclinonc.2016.9027296296
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506. doi:10.1056/NEJMoa140038225099575
   PubMed Web of Science ®Google Scholar
• Catucci I, Milgrom R, Kushnir A, et al. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Fam Cancer. 2012;11(3):483–491. doi:10.1007/s10689-012-9540-822692731
   PubMed Web of Science ®Google Scholar
• Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and fanconi anemia. Cancer Res. 2010;70(19):7353–7359. doi:10.1158/0008-5472.CAN-10-101220858716
   PubMed Web of Science ®Google Scholar
• Buisson R, Dion-Côté A-M, Coulombe Y, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol. 2010;17(10):1247–1254. doi:10.1038/nsmb.191520871615
   PubMed Web of Science ®Google Scholar
• Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011;10(1):3–8. doi:10.1158/1535-7163.MCT-10-089321135251
   PubMed Web of Science ®Google Scholar
• Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998;391(6663):184–187. doi:10.1038/344329428765
   PubMed Web of Science ®Google Scholar
• Beggs AD, Latchford AR, Vasen HFA, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59(7):975–986. doi:10.1136/gut.2009.19849920581245
   PubMed Web of Science ®Google Scholar
• Lu H-M, Li S, Black MH, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. JAMA Oncol. 2019;5(1):51–57. doi:10.1001/jamaoncol.2018.295630128536
   PubMed Web of Science ®Google Scholar
• Walsh MD, Buchanan DD, Cummings MC, et al. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res. 2010;16(7):2214–2224. doi:10.1158/1078-0432.CCR-09-305820215533
   PubMed Web of Science ®Google Scholar
• Shulman LP. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, lynch syndrome, cowden syndrome, and Li-Fraumeni syndrome. Obstet Gynecol Clin North Am. 2010;37(1):109–133, Table of Contents. doi:10.1016/j.ogc.2010.03.00320494261
   PubMed Web of Science ®Google Scholar
• Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30(9):958–964. doi:10.1200/JCO.2011.39.559022331944
   PubMed Web of Science ®Google Scholar
• Win AK, Lindor NM, Jenkins MA. Risk of breast cancer in lynch syndrome: a systematic review. Breast Cancer Res. 2013;15(2):R27. doi:10.1186/bcr340523510156
   PubMed Web of Science ®Google Scholar
• Win AK, Macinnis RJ, Dowty JG, Jenkins MA. Criteria and prediction models for mismatch repair gene mutations: a review. J Med Genet. 2013;50(12):785–793. doi:10.1136/jmedgenet-2013-10180323956446
   PubMed Web of Science ®Google Scholar
• Harkness EF, Barrow E, Newton K, et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. J Med Genet. 2015;52(8):553–556. doi:10.1136/jmedgenet-2015-10321626101330
   PubMed Web of Science ®Google Scholar
• Roberts ME, Jackson SA, Susswein LR, et al. MSH6 and PMS2 germ-line pathogenic variants implicated in lynch syndrome are associated with breast cancer. Genet Med. 2018;20(10):1167–1174. doi:10.1038/gim.2017.254f29345684
   PubMed Web of Science ®Google Scholar
• Anbazhagan R, Fujii H, Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin Cancer Res. 1999;5(4):839–844.10213220
   PubMed Web of Science ®Google Scholar
• Cortes-Ciriano I, Lee S, Park W-Y, Kim T-M, Park PJ. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017;8:15180. doi:10.1038/ncomms1518028585546
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan673328596308
   PubMed Web of Science ®Google Scholar
• Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. Abstract - Europe PMC. Available from: https://europepmc.org/article/med/29285544. Accessed 47, 2020.
   Google Scholar
• Moldovan G-L, D’Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet. 2009;43:223–249. doi:10.1146/annurev-genet-102108-13422219686080
   PubMed Web of Science ®Google Scholar
• Kuschel B, Auranen A, Gregory CS, et al. Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12(8):809–812.12917215
   PubMed Web of Science ®Google Scholar
• Xiang H, Geng X, Ge W, Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer. 2011;47(17):2546–2551. doi:10.1016/j.ejca.2011.03.02521807500
   PubMed Web of Science ®Google Scholar
• Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55–59. doi:10.1038/ng87911967536
   PubMed Web of Science ®Google Scholar
• Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study. J Clin Oncol. 2016;34(11):1208–1216. doi:10.1200/JCO.2015.63.359426884562
   PubMed Web of Science ®Google Scholar
• Cybulski C, Górski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–1135. doi:10.1086/42640315492928
   PubMed Web of Science ®Google Scholar
• Schmidt MK, Tollenaar RAEM, de Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25(1):64–69. doi:10.1200/JCO.2006.06.302417132695
   PubMed Web of Science ®Google Scholar
• Guénard F, Pedneault CS-L, Ouellette G, et al. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Genet Test Mol Biomarkers. 2010;14(4):515–526. doi:10.1089/gtmb.2010.002720722467
   PubMed Web of Science ®Google Scholar
• Weischer M, Nordestgaard BG, Pharoah P, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol. 2012;30(35):4308–4316. doi:10.1200/JCO.2012.42.733623109706
   PubMed Web of Science ®Google Scholar
• Schmidt MK, Hogervorst F, van Hien R, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC Carriers. J Clin Oncol. 2016;34(23):2750–2760. doi:10.1200/JCO.2016.66.584427269948
   PubMed Web of Science ®Google Scholar
• Cybulski C, Wokołorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29(28):3747–3752. doi:10.1200/JCO.2010.34.077821876083
   PubMed Web of Science ®Google Scholar
• Knappskog S, Chrisanthar R, Løkkevik E, et al. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res. 2012;14(2):R47. doi:10.1186/bcr314722420423
   PubMed Web of Science ®Google Scholar
• Chrisanthar R, Knappskog S, Løkkevik E, et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One. 2008;3(8):e3062. doi:10.1371/journal.pone.000306218725978
   PubMed Web of Science ®Google Scholar
• Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer. 2014;111(5):1004–1013. doi:10.1038/bjc.2014.30624918820
   PubMed Web of Science ®Google Scholar
• Kriege M, Jager A, Hollestelle A, et al. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers. J Cancer Res Clin Oncol. 2015;141(10):1879–1887. doi:10.1007/s00432-015-1981-725958056
   PubMed Web of Science ®Google Scholar
• Baeyens A, Claes K, Willems P, De Ruyck K, Thierens H, Vral A. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation. Cancer Genet Cytogenet. 2005;163(2):106–112. doi:10.1016/j.cancergencyto.2005.04.01716337852
   PubMedGoogle Scholar
• Reiner AS, Robson ME, Mellemkjær L, et al. Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants and risk of contralateral breast cancer. J Natl Cancer Inst. 2020. doi:10.1093/jnci/djaa031
   Google Scholar
• Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873–875. doi:10.1038/ng183716832357
   PubMed Web of Science ®Google Scholar
• Chenevix-Trench G, Spurdle AB, Gatei M, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002;94(3):205–215. doi:10.1093/jnci/94.3.20511830610
   PubMedGoogle Scholar
• Paglia LL, Laugé A, Weber J, et al. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy. Breast Cancer Res Treat. 2010;119(2):443–452. doi:10.1007/s10549-009-0396-z19404735
   PubMed Web of Science ®Google Scholar
• Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–46. doi:10.1158/2159-8290.CD-11-019422585167
   PubMed Web of Science ®Google Scholar
• Mansfield SA, Pilarski R, Agnese DM. ATM mutations for surgeons. Fam Cancer. 2017;16(3):407–410. doi:10.1007/s10689-016-9959-427988859
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Concannon P. ATM, radiation, and the risk of second primary breast cancer. Int J Radiat Biol. 2017;93(10):1121–1127. doi:10.1080/09553002.2017.134436328627265
   PubMed Web of Science ®Google Scholar
• Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 1999;286(5442):1162–1166. doi:10.1126/science.286.5442.116210550055
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the women’s environmental cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2010;102(7):475–483. doi:10.1093/jnci/djq05520305132
   PubMedGoogle Scholar
• Modlin LA, Flynn J, Zhang Z, et al. Breast radiotherapy among ATM-mutation carriers. JCO. 2019;37(15_suppl):1504. doi:10.1200/JCO.2019.37.15_suppl.1504
   Web of Science ®Google Scholar
• van Os NJH, Roeleveld N, Weemaes CMR, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016;90(2):105–117. doi:10.1111/cge.1271026662178
   PubMed Web of Science ®Google Scholar
• Paluch-Shimon S, Pagani O, Partridge AH, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203–217. doi:10.1016/j.breast.2017.07.01728822332
   PubMed Web of Science ®Google Scholar
• Teng P, Bateman NW, Darcy KM, et al. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol Oncol. 2015;136(3):554–561. doi:10.1016/j.ygyno.2014.12.03525560806
   PubMed Web of Science ®Google Scholar
• Ma Z, Yao G, Zhou B, Fan Y, Gao S, Feng X. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo. Mol Med Rep. 2012;6(4):897–903. doi:10.3892/mmr.2012.99922825736
   PubMed Web of Science ®Google Scholar
• Bridge WL, Vandenberg CJ, Franklin RJ, Hiom K. The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat Genet. 2005;37(9):953–957. doi:10.1038/ng162716116421
   PubMed Web of Science ®Google Scholar
• Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38(11):1239–1241. doi:10.1038/ng190217033622
   PubMed Web of Science ®Google Scholar
• Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104–1107. doi:10.1038/ng.95521964575
   PubMed Web of Science ®Google Scholar
• Song H, Ramus SJ, Kjaer SK, et al. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One. 2007;2(3):e268. doi:10.1371/journal.pone.000026817342202
   PubMed Web of Science ®Google Scholar
• Easton DF, Lesueur F, Decker B, et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet. 2016;53(5):298–309. doi:10.1136/jmedgenet-2015-10352926921362
   PubMed Web of Science ®Google Scholar